SCHEMBL30765612

SCHEMBL30765612

CSc1ncc(NCCCCOc2ccccc2)c(=O)n1CC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
F2 P00734 1/20 0.37
TSHR P16473 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MAPT P10636 1/20 0.35
FGFR1 P11362 2/20 0.35
KDR P35968 2/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
CA12 O43570 3/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA9 Q16790 3/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
JAK3 P52333 1/20 0.34
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765644 0.88 KDM4E (0.42) KDM4EALDH1A1F2
SCHEMBL30766080 0.87 MEN1 (0.45) KDM4EALDH1A1TSHRMAPTL3MBTL1
SCHEMBL30765554 0.86 KDM4E (0.44) KDM4EALDH1A1F2L3MBTL1
SCHEMBL23460591 0.86 KDM4E (0.43) KDM4EALDH1A1F2
SCHEMBL30765606 0.77 MEN1 (0.44) KDM4EALDH1A1TSHRMAPTL3MBTL1
SCHEMBL23474380 0.76 KDM4E (0.41) KDM4EALDH1A1F2JAK2JAK1
SCHEMBL30765933 0.76 KDM4C (0.45) KDM4EALDH1A1TSHRMAPTJAK2
SCHEMBL30765833 0.75 JAK2 (0.38) KDM4EALDH1A1F2JAK2JAK1
SCHEMBL30765873 0.74 KDM4E (0.41) KDM4EALDH1A1F2
SCHEMBL30765994 0.74 ELANE (0.46) KDM4EALDH1A1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed